BR112021022621A2 - Proteína mutante il-2 proliferando células imunes - Google Patents

Proteína mutante il-2 proliferando células imunes

Info

Publication number
BR112021022621A2
BR112021022621A2 BR112021022621A BR112021022621A BR112021022621A2 BR 112021022621 A2 BR112021022621 A2 BR 112021022621A2 BR 112021022621 A BR112021022621 A BR 112021022621A BR 112021022621 A BR112021022621 A BR 112021022621A BR 112021022621 A2 BR112021022621 A2 BR 112021022621A2
Authority
BR
Brazil
Prior art keywords
protein
mutant
immune cells
affinity
mutant protein
Prior art date
Application number
BR112021022621A
Other languages
English (en)
Inventor
Hu Hui
Zhang Ying
Original Assignee
Shanghai Gp Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Gp Biotech Co Ltd filed Critical Shanghai Gp Biotech Co Ltd
Publication of BR112021022621A2 publication Critical patent/BR112021022621A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROTEÍNA MUTANTE IL-2 PROLIFERANDO CÉLULAS IMUNES. São fornecidos na presente invenção uma proteína mutante de IL-2, uma proteína de fusão ou conjugado contendo a proteína mutante de IL-2 e uma composição farmacêutica contendo a proteína mutante de IL-2, proteína de fusão ou conjugado. Em comparação com a proteína IL-2 de tipo selvagem, a proteína mutante IL-2 da presente invenção elimina ou reduz a afinidade para um receptor de IL-2 de alta afinidade e retém substancialmente a afinidade para um receptor de IL-2 de afinidade média.
BR112021022621A 2019-05-14 2020-05-14 Proteína mutante il-2 proliferando células imunes BR112021022621A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910399641.1A CN111944036A (zh) 2019-05-14 2019-05-14 一种增殖免疫细胞的突变体蛋白
PCT/CN2020/090365 WO2020228791A1 (zh) 2019-05-14 2020-05-14 增殖免疫细胞的il-2突变体蛋白

Publications (1)

Publication Number Publication Date
BR112021022621A2 true BR112021022621A2 (pt) 2022-07-19

Family

ID=73289362

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022621A BR112021022621A2 (pt) 2019-05-14 2020-05-14 Proteína mutante il-2 proliferando células imunes

Country Status (10)

Country Link
US (1) US20220227829A1 (pt)
EP (1) EP3971205A4 (pt)
JP (1) JP2022533636A (pt)
KR (1) KR20220008323A (pt)
CN (2) CN111944036A (pt)
AU (1) AU2020274833A1 (pt)
BR (1) BR112021022621A2 (pt)
CA (1) CA3139833A1 (pt)
SG (1) SG11202112710VA (pt)
WO (1) WO2020228791A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4130027A1 (en) * 2020-03-31 2023-02-08 Hanmi Pharm. Co., Ltd. Novel immunoactive interleukin 2 analog
CN113667003A (zh) * 2020-05-14 2021-11-19 上海盖浦生物科技有限公司 一种增殖调节性t细胞的突变体蛋白

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
WO2003015697A2 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
NZ548612A (en) * 2004-02-09 2009-11-27 Human Genome Sciences Inc Albumin fusion proteins comprising tandem GLP-1
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
AU2011218682B2 (en) * 2005-05-11 2013-11-21 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
PT2066796E (pt) 2006-09-20 2011-10-11 Mt Biomethan Gmbh Procedimento e dispositivo para a separação do metano e do dióxido de carbono do biogás
US20110154516A1 (en) * 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
JP2016519651A (ja) * 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
CN104231068A (zh) * 2014-01-27 2014-12-24 苏州发士达生物科技有限公司 人白细胞介素ii突变体及其应用
EP3102595B1 (en) * 2014-02-06 2018-11-07 F.Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
MA40721A (fr) 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CN116472281A (zh) * 2020-04-28 2023-07-21 安维塔生物科学股份有限公司 白介素-2多肽及其融合蛋白，及其药物组合物和治疗应用

Also Published As

Publication number Publication date
CA3139833A1 (en) 2020-11-19
WO2020228791A1 (zh) 2020-11-19
CN113939528A (zh) 2022-01-14
EP3971205A4 (en) 2023-09-06
EP3971205A1 (en) 2022-03-23
US20220227829A1 (en) 2022-07-21
CN111944036A (zh) 2020-11-17
AU2020274833A1 (en) 2022-01-06
SG11202112710VA (en) 2021-12-30
JP2022533636A (ja) 2022-07-25
KR20220008323A (ko) 2022-01-20

Similar Documents

Publication Publication Date Title
MX2021007368A (es) Anticuerpos anti-receptor de transferrina y usos de los mismos.
BR112021022621A2 (pt) Proteína mutante il-2 proliferando células imunes
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
BR0214650A (pt) Imunocitoquinas com seletividade modulada
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
WO2018134691A8 (en) CELL SURFACE CONJUGATES AND CELLULAR COMPOSITIONS AND ASSOCIATED METHODS
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
BR112022014771A2 (pt) Anticorpo anti-receptor de transferrina (tfr) e usos do mesmo
BRPI0511616A (pt) compostos
WO2019094395A3 (en) Hydrophilic linkers for antibody drug conjugates
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
MY158857A (en) Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparation and compositions including the same, and methods
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
BRPI0518542A2 (pt) regimes para viscossuplementaÇço intra-articular
BR112018073280A2 (pt) cd200 mutantes e seus usos
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
FI20225221A1 (fi) Ei-eläinperhjaisia proteiinilähteitä funktionaalisilla ominaisuuksilla
MX2023007282A (es) Moleculas de union al antigeno especificas para la variante ror1.
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
BR112022006440A2 (pt) Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
MX2023004032A (es) Terapias inmuno-oncologicas con conjugados de il-2.
PH12021550082A1 (en) Fcrn antibody compositions
WO2018175740A8 (en) Anti-tmeff1 antibodies and antibody drug conjugates